Navigation Links
Regado Biosciences, Inc. to Provide Third Quarter 2013 Financial Results
Date:10/31/2013

BASKING RIDGE, N.J., Oct. 31, 2013 /PRNewswire/ -- Regado Biosciences, Inc. (Nasdaq: RGDO), a biopharmaceutical company focused on the late-stage clinical development of its first-in-class, actively controllable antithrombotic drug system, REG1, today announced Regado's senior management will host a third quarter earnings conference call and live audio webcast on Thursday, November 7, 2013, at 8:30 a.m. ET to discuss recent activities and upcoming plans.

Interested participants and investors may access the conference call by dialing (877) 870-4263 (U.S.), (855) 669-9657 (Canada) or (412) 317-0790 (international). An audio webcast will be accessible via the Investor Relations section of the Regado website, www.regadobio.com.  

A telephonic replay of the call will be available for 90 days beginning approximately one hour following the end of the conference call.  Access numbers for this replay are (877) 344-7529 (U.S./Canada) and (412) 317-0088 (international); conference ID: 10036564. The webcast replay will remain available for 90 days in the Investor Relations section of the Regado website.

ABOUT REGADO BIOSCIENCES
Regado Biosciences, Inc. is a biopharmaceutical company focused on the development of novel, first-in-class, actively controllable antithrombotic drug systems for acute and sub-acute cardiovascular indications.  Regado is pioneering the development of two-component drug systems consisting of a therapeutic aptamer and its specific active control agent. The company's lead product candidate, REG1, is a two-component system consisting of pegnivacogin, an anticoagulant aptamer specifically targeting coagulation Factor IXa, and its complementary oligonucleotide active control agent, anivamersen.  REG1 is being developed for use in patients with a wide variety of acute coronary syndromes, or ACS, undergoing a percutaneous coronary intervention, or PCI, a hospital-based procedure used to mechanically open or widen obstructed coronary arteries. Regado's actively controllable product candidates have the potential to improve patient outcomes, enhance the patient experience and reduce overall treatment costs. More information can be found at www.regadobio.com.

For more information on Regado's Phase 3 REGULATE-PCI clinical study, please visit:
http://www.clinicaltrials.gov/ct2/show/NCT01848106?term=Regado&rank=1

Contact:

Tiberend Strategic Advisors, Inc.

Investors - Joshua Drumm, Ph.D.
jdrumm@tiberend.com; (212) 375-2664

Media - Andrew Mielach
amielach@tiberend.com; (212) 375-2694


'/>"/>
SOURCE Regado Biosciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Regado Biosciences, Inc. to Present at the Cowen and Company 32nd Annual Health Care Conference in Boston, MA
2. Regado Biosciences, Inc. to Present at Needham & Companys 11th Annual Healthcare Conference in New York, NY
3. Regado Biosciences, Inc. Files Registration Statement for Proposed Initial Public Offering
4. Regado Biosciences, Inc. Announces Exercise of Over-Allotment Option
5. Regado Biosciences, Inc. to Present at Aegis Capital Vegas Healthcare Conference
6. Shire to Acquire FerroKin BioSciences, Inc., and its Phase 2 Iron Chelator Treatment
7. Pressure BioSciences, Inc. Reaches Agreement with Investors on Initial $600,000 Tranche of $1.2 Million Above-Market Private Placement; Proceeds to Support Continued Commercialization of PCT Product Platform
8. Pressure BioSciences, Inc. Continues Global Sales Reach Expansion with Distribution Agreements for China, Vietnam, Laos, Cambodia, Australia, and New Zealand
9. Pressure BioSciences, Inc. Appoints Conrad F. Mir as Chief Financial Officer
10. Pressure BioSciences, Inc. to Discuss First Quarter 2013 Financial Results and Provide Business Update
11. Pressure BioSciences, Inc. Closes Final Tranche of Series J Above Market Private Placement - Total Amount Raised in PIPE Slightly Exceeds $2 Million Goal
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... 2017 , ... Proscia Inc ., a data solutions ... “Pathology is going digital. Is your lab ready?” with Dr. Nicolas Cacciabeve, Managing ... how Proscia improves lab economics and realizes an increase in diagnostic confidence.* ...
(Date:10/11/2017)... ... October 11, 2017 , ... Disappearing forests and increased emissions are ... 5.5 million people each year. Especially those living in larger cities are affected by ... in one of the most pollution-affected countries globally - decided to take action. , ...
(Date:10/10/2017)... ... 2017 , ... San Diego-based team building and cooking events company, Lajollacooks4u, has ... The bold new look is part of a transformation to increase awareness, appeal to ... period. , It will also expand its service offering from its signature gourmet cooking ...
(Date:10/10/2017)... ... ... Dr. Bob Harman, founder and CEO of VetStem Biopharma, Inc. ... event entitled “Stem Cells and Their Regenerative Powers,” was held on August 31st, ... was joined by two human doctors: Peter B. Hanson, M.D., Chief of Orthopedic Surgery, ...
Breaking Biology Technology:
(Date:7/20/2017)... 20, 2017 Delta (NYSE: DAL ) customers now ... aircraft at Reagan Washington National Airport (DCA). ... Delta launches biometrics to board aircraft at ... Delta,s biometric boarding pass experience ... is now integrated into the boarding process to allow eligible Delta SkyMiles ...
(Date:6/14/2017)... IBM ) is introducing several innovative partner startups at ... between startups and global businesses, taking place in ... startups will showcase the solutions they have built with IBM ... France is one of the most ... increase in the number of startups created between 2012 and ...
(Date:5/16/2017)... 2017   Bridge Patient Portal , an ... MD EMR Systems , an electronic medical record ... have established a partnership to build an interface ... GE Centricity™ products, including Centricity Practice Solution (CPS), ... These new integrations will allow healthcare delivery networks ...
Breaking Biology News(10 mins):